---
document_datetime: 2025-03-20 15:55:06
document_pages: 18
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/mounjaro-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: mounjaro-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 8.275104
conversion_datetime: 2025-12-26 08:59:15.864429
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Mounjaro

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                            | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|--------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| N/0041               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 26/02/2025                          |                                             | Labelling and PL                 |                                                                                                                                            |
| PSUSA/11019 /202405  | Periodic Safety Update EU Single assessment - tirzepatide                                        | 12/12/2024                          | 14/02/2025                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/11019/202405. |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0037/G   | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 16/01/2025   | n/a   |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IB/0040/G   | This was an application for a group of variations. B.I.e.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supportive data B.I.e.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supportive data B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.e.5.b - Implementation of changes foreseen in an approved change management protocol - Requires further supportive data | 09/01/2025   | n/a   |

<div style=\"page-break-after: always\"></div>

| IB/0039/G   | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place   | 09/01/2025   | n/a        |             |                                                                      |
|-------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|----------------------------------------------------------------------|
| II/0027     | Update of sections 4.1, 4.8 and 5.1 of the SmPC based on final results from studies I8F-MC-GPI1 and I8F-MC-GPI2. These are multicentre, randomized, parallel-arm, double-blind, placebo-controlled studies investigating the effects of tirzepatide compared with placebo in adult participants with moderate-to- severe OSA and obesity. The Package Leaflet is updated accordingly. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one                    | 12/12/2024   | 14/02/2025 | SmPC and PL | Please refer to Scientific Discussion 'Mounjaro-H-C-005620- II-0027' |
| IB/0036/G   | This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any                                                                                                                                                                                                                                                                                                                                                 | 22/11/2024   | n/a        |             |                                                                      |

<div style=\"page-break-after: always\"></div>

|             | take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |            |                 | manufacturing operation(s)   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------|
| IAIN/0035   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                   | 02/10/2024 | 14/02/2025 | SmPC and PL     |                              |
| IAIN/0034/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing     | 02/10/2024 | 14/02/2025 | Annex II and PL |                              |
| IB/0031/G   | This was an application for a group of variations. B.II.b.4.z - Change in the batch size (including batch size ranges) of the finished product - Other variation B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process Implementation of changes foreseen in                                                      | 19/09/2024 | n/a        |                 | B.II.g.5.b -                 |

<div style=\"page-break-after: always\"></div>

|                     | an approved change management protocol - Requires further supporting data B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                                                             |            |            |             |                                                                                                                                            |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0033           | B.I.e.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supportive data                                                                                                                                                                                                                                                   | 30/08/2024 | n/a        |             |                                                                                                                                            |
| PSUSA/11019 /202311 | Periodic Safety Update EU Single assessment - tirzepatide                                                                                                                                                                                                                                                                                                                        | 27/06/2024 | 22/08/2024 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/11019/202311. |
| IA/0032             | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                                                                                                       | 21/08/2024 | n/a        |             |                                                                                                                                            |
| IA/0030             | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                                                                                                       | 21/08/2024 | n/a        |             |                                                                                                                                            |
| IB/0028/G           | This was an application for a group of variations. B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a | 14/08/2024 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|             | corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |            |             | its   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------|
| II/0022     | B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 25/07/2024 | n/a        |             |       |
| II/0021/G   | This was an application for a group of variations. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 25/07/2024 | 14/02/2025 | SmPC and PL |       |
| IAIN/0026/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 19/07/2024 | n/a        |             |       |

<div style=\"page-break-after: always\"></div>

|             | of changes foreseen in an approved change management protocol - Requires no further supportive data B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS   |            |            |                 | B.I.e.5.a - Implementation   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|------------------------------|
| IB/0025/G   | This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                    | 04/07/2024 | 14/02/2025 | Annex II and PL |                              |
| IAIN/0024/G | This was an application for a group of variations. B.I.e.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supportive data B.I.e.5.a - Implementation of changes foreseen in an approved change management protocol - Requires supportive data                                                                                                                                                    | 21/06/2024 | n/a        |                 | no further                   |

<div style=\"page-break-after: always\"></div>

|             | B.I.e.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supportive data B.I.e.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supportive data                                                                                                                                |            |            |                                  |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| IAIN/0023/G | This was an application for a group of variations. B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing | 11/06/2024 | 22/08/2024 | Annex II and PL                  |
| X/0015      | Extension application to add 6 new strengths of 2.5 mg/dose (4.17 mg/ml), 5 mg/dose (8.33 mg/ml), 7.5 mg/dose (12.5 mg/ml), 10 mg/dose (16.67 mg/ml), 12.5 mg/dose (20.83 mg/ml) and 15 mg/dose (25 mg/ml) for Mounjaro solution for injection in pre-filled pen (KwikPen), multidose. Annex I_2.(c) Change or addition of a new strength/potency                                            | 22/02/2024 | 19/04/2024 | SmPC, Annex II, Labelling and PL |
| IB/0020     | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                   | 05/03/2024 | n/a        |                                  |

<div style=\"page-break-after: always\"></div>

| IAIN/0019/G   | This was an application for a group of variations. B.I.e.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supportive data B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS   | 29/02/2024   | n/a        |                 |                                                                  |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|------------------------------------------------------------------|
| IAIN/0017/G   | This was an application for a group of variations. B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                 | 10/01/2024   | 19/04/2024 | Annex II and PL |                                                                  |
| II/0007       | Extension of indication to include chronic weight management, including weight loss and weight maintenance, for MOUNJARO, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of ≥ 30 kg/m2 (obesity), or ≥ 27 kg/m2 to < 30 kg/m2                                                                                                                                                                                                                                                                       | 09/11/2023   | 11/12/2023 | SmPC and PL     | Please refer to Scientific Discussion 'EMEA-H-C-005620-II- 0007' |

<div style=\"page-break-after: always\"></div>

|                     | (overweight) in the presence of at least one weight- related comorbid condition, based on a global, pivotal phase 3 study I8F-MC-GPHK (SURMOUNT-1) and five supportive phase 3 studies (SURPASS-1 to - 5) in participants with T2DM and BMI ≥ 27 kg/m2. SURMOUNT-1 is a phase 3, randomized, double- blind, placebo-controlled trial to investigate the efficacy and safety of tirzepatide once weekly in participants without type 2 diabetes who have obesity or are overweight with weight related comorbidities. As a consequence, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or   |            |            |             |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-----------------------------------|
| PSUSA/11019 /202305 | Periodic Safety Update EU Single assessment - tirzepatide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 30/11/2023 | n/a        |             | PRAC Recommendation - maintenance |
| II/0010             | Update of section 4.8 of the SmPC in order to add 'anaphylactic reaction' and 'angioedema' to the list of adverse drug reactions (ADRs) with frequency rare, based on reviews of post-marketing safety data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the PI.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 09/11/2023 | 11/12/2023 | SmPC and PL | Not applicable                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|             | - Change(s) in the SPC, Labelling or PL due to quality, preclinical, clinical or pharmacovigilance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |                        | C.I.4 new data   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------|
| IAIN/0016/G | This was an application for a group of variations. B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished | 25/10/2023 | 11/12/2023 | SmPC, Labelling and PL |                  |

<div style=\"page-break-after: always\"></div>

tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g.

<div style=\"page-break-after: always\"></div>

tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g.

<div style=\"page-break-after: always\"></div>

|           | ampoules, etc.) in a pack - Change within range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |                        | tablets, the   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------|
| IAIN/0014 | B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 25/10/2023 | 11/12/2023 | SmPC, Labelling and PL |                |
| IB/0012   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 05/10/2023 | n/a        |                        |                |
| II/0006/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.a.1.c - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer uses a substantially different route of synthesis or manufacturing conditions B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.e.2 - Introduction of a post approval change management protocol related to the AS B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.I.d.1.a.2 - Stability of AS - Change in the re-test period/storage period - Extension of the retest period | 31/08/2023 | n/a        |                        |                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | accordance with ICH/VICH guidelines B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0004/G | This was an application for a group of variations. Please refer to the Recommendations section B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site B.II.b.4.b - Change in the batch size (including batch size ranges) of the finished product - Downscaling down to 10-fold B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products | 31/08/2023 | 11/12/2023 | SmPC, Labelling and PL | The SmPC, Annexes IIIA, IIIB and A has been updated to reflect the registration of new presentations: - EU/1/22/1685/019: 2.5 mg; 0.5 ml (5 mg/ml); vial (glass); 1 vial - EU/1/22/1685/020: 5 mg; 0.5 ml (10 mg/ml); vial (glass); 1 vial - EU/1/22/1685/021: 7.5 mg; 0.5 ml (15 mg/ml); vial (glass); 1 vial - EU/1/22/1685/022: 10 mg; 0.5 ml (20 mg/ml); vial (glass); 1 vial - EU/1/22/1685/023: 12.5 mg; 0.5 ml (25 mg/ml); vial (glass); 1 vial - EU/1/22/1685/024: 15 mg; 0.5 ml (30 mg/ml); vial (glass); 1 vial |

<div style=\"page-break-after: always\"></div>

|                     | finished product - Change in type/addition of a new container - Sterile medicinal products and biological/immunological medicinal products B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within the range of the currently approved pack sizes B.II.e.5.a.1 - Change in pack size of the finished product - Change in the number of units (e.g. tablets, ampoules, etc.) in a pack - Change within   |            |            |             |                                                                                                                                                             |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/11019 /202211 | Periodic Safety Update EU Single assessment - tirzepatide                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 22/06/2023 | 23/08/2023 | SmPC and PL | Please refer to Mounjaro PSUSA-11019-202211 EPAR: Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation |
| IB/0009/G           | This was an application for a group of variations. B.II.b.1.f - Replacement or addition of a manufacturing site for part or all of the                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 30/06/2023 | n/a        |             |                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|           | manufacturing process of the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/ immunological medicinal products B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.5.b - Change to in-process tests or limits applied during the manufacture of the finished product - Addition of a new test(s) and limits B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place   |            |            |                       |                |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------|
| II/0008   | Please refer to the Recommendations section B.I.e.2 - Introduction of a post approval change management protocol related to the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 29/06/2023 | n/a        |                       | Not applicable |
| IB/0005/G | This was an application for a group of variations. B.II.b.2.c.2 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site A.6 - Administrative change - Change in ATC                                                                                                                                                                                                                                                                                                       | 22/03/2023 | 23/08/2023 | SmPC, Annex II and PL |                |

<div style=\"page-break-after: always\"></div>

|           | Code/ATC Vet Code                                                                                                                                                                                                                                                                                                                                                                                                     |            |            |    |            |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----|------------|
| IB/0001/G | This was an application for a group of variations. B.II.e.z - Change in container closure system of the Finished Product - Other variation B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the Replacement or addition of a supplier | 03/03/2023 | n/a        |    | dossier) - |
| N/0003    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                      | 23/02/2023 | 23/08/2023 | PL |            |